Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Aug 29, 2024

BUY
$407.69 - $446.08 $76,645 - $83,863
188 New
188 $78,000
Q4 2023

Aug 29, 2024

BUY
$343.0 - $410.68 $64,484 - $77,207
188 New
188 $76,000
Q4 2023

Feb 28, 2024

BUY
$343.0 - $410.68 $20,923 - $25,051
61 New
61 $25,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track University Of Texas Portfolio

Follow University Of Texas and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of University Of Texas, based on Form 13F filings with the SEC.

News

Stay updated on University Of Texas with notifications on news.